[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100081216":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":18,"locations":23,"responsibleParty":40,"collaborators":44,"id":48,"slug":7,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":7,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":7,"maxAge":7,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University of Iowa","OTHER",null,[9,12,16],{"name":10,"affiliation":5,"role":11},"Katherine Mathews, M.D.","PRINCIPAL_INVESTIGATOR",{"name":13,"affiliation":14,"role":15},"Kevin Campbell, Ph.D.","Co-Investigator","STUDY_DIRECTOR",{"name":17,"affiliation":14,"role":15},"Steven A. Moore, M.D. Ph.D.",[19],{"name":20,"role":21,"phone":22,"phoneExt":7,"email":7},"Carrie Stephan, R.N. M.A.","CONTACT","(319) 356-2673",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"University of Iowa, 200 Hawkins Drive","RECRUITING","Iowa City","Iowa","52242","United States",{"type":32,"coordinates":33},"Point",[34,35],-91.53017,41.66113,{"lat":35,"lon":34},[38],{"name":20,"role":21,"phone":39,"phoneExt":7,"email":7},"(319)356-2673",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Katherine Mathews","Professor and Principal Investigator",[45],{"name":46,"class":47},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH","100081216",false,"NCT00313677","Clinical Trial Readiness for the Dystroglycanopathies","Inclusion Criteria:\n\n* Elevated CK (creatine kinase)\n* Evidence of a dystroglycanopathy as determined by review of muscle pathology OR documented mutation in one of the known genes OR abnormal alpha-dystroglycan glycosylation in cultured fibroblasts\n* Dystroglycanopathies are predicted to affect all racial and ethnic backgrounds, and all patients with dystroglycanopathies will be eligible for participation.\n* Participants may be of any age, including children, and males and females will be recruited equally.\n* Patients will have varying degrees of muscular weakness, but otherwise should be in relatively good health.\n\nExclusion Criteria:\n\n* There are no exclusion criteria.","ALL",{"count":55,"type":56},190,"ESTIMATED","OBSERVATIONAL","The purpose of the study is to describe the early signs and symptoms of the dystroglycanopathies, and to gather information that will be required for future clinical trials.",[60],"Muscular Dystrophy",[62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89],"muscular dystrophy","MD","fukutin-related protein gene","limb girdle","FKRP gene","congenital muscular dystrophy","childhood onset LGMD","adult onset LGMD","POMT1","POMT2","POMGnT1","LARGE","alpha dystroglycan","dystroglycanopathy","ISPD\u002FCRPPA","DPM 1, 2 or 3","GMPPB","B3GNT1\u002FB4GAT1","B3GALNT2","GTDC2\u002FPOMGnT2","TMEM5\u002FRXYLT1","Fukutin","DAG1","POMK\u002FSGK196","DOLK","TRAPPC11","GOSR2","INPP5K","2025-07-24",{"date":92,"type":93},"2025-07-30","ACTUAL",{"date":95,"type":7},"2006-04",{"date":97,"type":56},"2030-07",{"name":42,"class":6},1]